Table 5 |
||||
|
Adverse events (occurring after baseline but before recurrence of parasitaemia in > 2% of children) suspected by investigators to be related to study medication by body weight group |
||||
| Adverse Events |
n (%) |
|||
|
|
||||
| BWG1 5-<10 kg (N = 50) |
BWG2 10-<15 kg (N = 37) |
BWG3 15-<25 kg (N = 16) |
Total 5-<25 kg (N = 103) |
|
|
|
||||
| At least one adverse event |
30 (60.0) |
16 (43.2) |
6 (37.5) |
52 (50.5) |
| Anaemia |
7 (14.0) |
6 (16.2) |
1 (6.3) |
14 (13.6) |
| Diarrhoea |
5 (10.0) |
5 (13.5) |
1 (6.3) |
11 (10.7) |
| Clonus |
7 (14.0) |
5 (13.5) |
1 (6.3) |
13 (12.6) |
| Vomiting |
7 (14.0) |
0 (-) |
4 (25.0) |
11 (10.7) |
| Rashes |
4 (8.0) |
3 (8.1) |
0 (-) |
7 (6.8) |
| Hyperreflexia |
1 (2.0) |
2 (5.4) |
1 (6.3) |
4 (3.9) |
| Cough |
2 (4.0) |
1 (2.7) |
0 (-) |
3 (2.9) |
|
|
||||
|
Falade et al. Malaria Journal 2008 7:246 doi:10.1186/1475-2875-7-246 |
||||
